Antimicrobial Compositions with Effervescent Agents

1 - 50 . (canceled)

51 . A pharmaceutical composition comprising:

(a) a quinolone carboxylic acid derivative or a pharmaceutically acceptable salt or ester thereof; and

(b) an effervescent agent comprising:

(1) sodium bicarbonate;

(2) an acidic agent; and

(3) an alkaline agent selected from the group consisting of sodium carbonate, sodium phosphate, sodium hydrogen phosphate, sodium dihydrogen phosphate, sodium hydroxide, potassium carbonate, potassium bicarbonate, potassium hydrogen phosphate, potassium dihydrogen phosphate, potassium hydroxide, magnesium carbonate, magnesium hydroxide, magnesium oxide, calcium carbonate, calcium oxide, and mixtures thereof;

wherein said quinolone carboxylic acid derivative corresponds to the following compound (A)

or a pharmaceutically acceptable salt or ester thereof.

52 . The pharmaceutical composition of claim 51 , wherein said quinolone carboxylic acid derivative is a D-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo-3-quinolinecarboxylate.

53 . The pharmaceutical composition of claim 52 , wherein said quinolone carboxylic acid derivative is a crystalline D-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo-3-quinolinecarboxylate characterized by an X-ray powder diffraction pattern substantially in accordance with that shown in FIG. 1 , wherein the pattern is obtained from a copper radiation source (Cu—Kα, 40 kV, 4 mA).

54 . The pharmaceutical composition of claim 51 , wherein said quinolone carboxylic acid derivative is a crystalline D-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo-3-quinolinecarboxylate form characterized by an X-ray powder diffraction pattern comprising peaks at about 6.35, 12.70, 19.10, and 20.50 degrees 2θ, wherein the pattern is obtained from a copper radiation source (Cu—Kα, 40 kV, 4 mA).

55 . The pharmaceutical composition of claim 53 , wherein the crystalline D-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo-3-quinolinecarboxylate is characterized by a melting point of about 168-171° C.

56 . The pharmaceutical composition of claim 53 , wherein the crystalline D-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo-3-quinolinecarboxylate is characterized by the differential scanning calorimetry thermogram shown in FIG. 3 .

57 . The pharmaceutical composition of claim 51 , wherein the alkaline agent comprises sodium dihydrogen phosphate.

58 . The pharmaceutical composition of claim 51 , wherein the acidic agent comprises a compound selected from the group consisting of citric acid, sodium citrate, potassium citrate, maleic acid, maleic anhydride, sodium malate, potassium malate, tartaric acid, sodium tartrate, potassium tartrate, fumaric acid, sodium fumarate, potassium fumarate, ascorbic acid, sodium ascorbate, potassium ascorbate, and mixtures thereof.

59 . The pharmaceutical composition of claim 58 , wherein the effervescent agent comprises a mixture of sodium bicarbonate, sodium dihydrogen phosphate and citric acid.

60 . The pharmaceutical composition of claim 59 , further comprising a polyhydroxyamine compound.

61 . The pharmaceutical composition of claim 60 , wherein said polyhydroxyamine compound is meglumine.

62 . The pharmaceutical composition of claim 51 , comprising:

(a) from about 100 mg to about 750 mg of said quinolone carboxylic acid derivative, on an acid active basis, wherein said quinolone carboxylic acid derivative is delafloxacin or a pharmaceutically acceptable salt thereof; and

(b) from about 100 mg to about 500 mg of the effervescent agent.

63 . The pharmaceutical composition of claim 62 , wherein said effervescent agent comprises a mixture of sodium bicarbonate, sodium dihydrogen phosphate, and citric acid.

64 . The pharmaceutical composition of claim 51 comprising:

(a) about 650 mg of said quinolone carboxylic acid derivative, wherein said quinolone carboxylic acid derivative is delafloxacin meglumine; and

(b) about 150 mg of said effervescent agent, wherein said effervescent agent comprises a mixture of sodium bicarbonate, sodium dihydrogen phosphate, and citric acid.

65 . The pharmaceutical composition of claim 51 in the form of a tablet or a capsule.

66 . The pharmaceutical composition of claim 65 , wherein the tablet is a single layer tablet or a bilayer tablet comprising a first layer and a second layer.

67 . The pharmaceutical composition of claim 66 , wherein the tablet is a bilayer tablet and said first layer comprises said quinolone carboxylic acid derivative or a pharmaceutically acceptable salt thereof and said second layer comprises said effervescent agent.

68 . A method for treating or reducing the risk of a bacterial infection comprising administering to a patient in need thereof an effective amount of the composition of claim 51 .

69 . The pharmaceutical composition of claim 51 , comprising:

(a) the quinolone carboxylic acid derivative, wherein the quinolone carboxylic acid derivative is delafloxacin meglumine;

(b) microcrystalline cellulose;

(c) povidone;

(d) crospovidone;

(e) sodium bicarbonate;

(f) sodium dihydrogen phosphate

(g) citric acid; and

(h) magnesium stearate.

70 . The pharmaceutical composition of claim 66 , wherein the tablet is a single layer tablet.

71 . The pharmaceutical composition of claim 69 , wherein the tablet is a single layer tablet.

72 . The pharmaceutical composition of claim 69 , wherein the tablet is a tablet comprising a first layer and a second layer.

73 . The pharmaceutical composition of claim 51 , wherein the acidic agent comprises citric acid.